Literature DB >> 12821487

Detection of nucleotide variability in rpoB in both rifampin-sensitive and rifampin-resistant strains of Chlamydia trachomatis.

Ute Dreses-Werringloer1, Ingrid Padubrin, Lars Köhler, Alan P Hudson.   

Abstract

A 656-bp PCR fragment from rpoB was sequenced from five rifampin-resistant Chlamydia trachomatis variants selected in vitro from a wild-type parent with a surprising level of genetic variability in this region. Three variants (MIC, 4 microg/ml) showed Ala522-->Val in cluster I (codons 507 to 533), which harbors mutations in most rifampin-resistant bacteria. Two high-level resistance variants (MICs, 64 and 256 microg/ml) showed His526-->Tyr in cluster I with additional genetic variation, some of which resulted in amino acid substitutions. None of the latter was situated in clusters related to rifampin resistance in other bacteria.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12821487      PMCID: PMC161851          DOI: 10.1128/AAC.47.7.2316-2318.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus.

Authors:  T A Wichelhaus; V Schäfer; V Brade; B Böddinghaus
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

2.  rpoB mutation conferring rifampin resistance in Streptococcus pyogenes.

Authors:  Hélène Aubry-Damon; Marc Galimand; Guy Gerbaud; Patrice Courvalin
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

3.  Molecular characterization of rifampin-resistant isolates of Mycobacterium tuberculosis from Hungary by DNA sequencing and the line probe assay.

Authors:  Z Bártfai; A Somoskövi; C Ködmön; N Szabó; E Puskás; L Kosztolányi; E Faragó; J Mester; L M Parsons; M Salfinger
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

4.  Antibiotic susceptibility of Chlamydia trachomatis.

Authors:  H J Blackman; C Yoneda; C R Dawson; J Schachter
Journal:  Antimicrob Agents Chemother       Date:  1977-12       Impact factor: 5.191

5.  Molecular basis of rifampin resistance in Streptococcus pneumoniae.

Authors:  T Padayachee; K P Klugman
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

6.  Emergence of rifampin-resistance in Chlamydia trachomatis.

Authors:  H Keshishyan; L Hanna; E Jawetz
Journal:  Nature       Date:  1973-07-20       Impact factor: 49.962

7.  Structural mechanism for rifampicin inhibition of bacterial rna polymerase.

Authors:  E A Campbell; N Korzheva; A Mustaev; K Murakami; S Nair; A Goldfarb; S A Darst
Journal:  Cell       Date:  2001-03-23       Impact factor: 41.582

8.  Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates.

Authors:  M Heep; B Brandstätter; U Rieger; N Lehn; E Richter; S Rüsch-Gerdes; S Niemann
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

9.  Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro.

Authors:  U Dreses-Werringloer; I Padubrin; H Zeidler; L Köhler
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

10.  The antimicrobial susceptibility of Chlamydia trachomatis in cell culture.

Authors:  G L Ridgway; J M Owen; J D Oriel
Journal:  Br J Vener Dis       Date:  1978-04
View more
  15 in total

Review 1.  Antibiotic resistance in Chlamydiae.

Authors:  Kelsi M Sandoz; Daniel D Rockey
Journal:  Future Microbiol       Date:  2010-09       Impact factor: 3.165

2.  Rifampin-resistant RNA polymerase mutants of Chlamydia trachomatis remain susceptible to the ansamycin rifalazil.

Authors:  Robert J Suchland; Agnès Bourillon; Erick Denamur; Walter E Stamm; David M Rothstein
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

3.  Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis.

Authors:  Andrei Kutlin; Stephan Kohlhoff; Patricia Roblin; Margaret R Hammerschlag; Paul Riska
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  Generation of targeted Chlamydia trachomatis null mutants.

Authors:  Laszlo Kari; Morgan M Goheen; Linnell B Randall; Lacey D Taylor; John H Carlson; William M Whitmire; Dezso Virok; Krithika Rajaram; Valeria Endresz; Grant McClarty; David E Nelson; Harlan D Caldwell
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

5.  Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile.

Authors:  Jamie S Huang; Zhi-Dong Jiang; Kevin W Garey; Todd Lasco; Herbert L Dupont
Journal:  Antimicrob Agents Chemother       Date:  2013-04-01       Impact factor: 5.191

6.  Activities of rifamycin derivatives against wild-type and rpoB mutants of Chlamydia trachomatis.

Authors:  Minsheng Xia; Robert J Suchland; Joli A Carswell; John Van Duzer; Debra K Buxton; Kara Brown; David M Rothstein; Walter E Stamm
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

7.  Growth cycle-dependent pharmacodynamics of antichlamydial drugs.

Authors:  Katrin Siewert; Jan Rupp; Matthias Klinger; Werner Solbach; Jens Gieffers
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

8.  The effect of rifaximin on gut flora and Staphylococcus resistance.

Authors:  Mi-Sung Kim; Walter Morales; Andres Ardila Hani; Sharon Kim; Gene Kim; Stacy Weitsman; Christopher Chang; Mark Pimentel
Journal:  Dig Dis Sci       Date:  2013-04-16       Impact factor: 3.199

9.  Initial characterization of Chlamydophila (Chlamydia) pneumoniae cultured from the late-onset Alzheimer brain.

Authors:  Ute Dreses-Werringloer; Mohammad Bhuiyan; Yinghao Zhao; Hervé C Gérard; Judith A Whittum-Hudson; Alan P Hudson
Journal:  Int J Med Microbiol       Date:  2008-09-30       Impact factor: 3.473

10.  In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus.

Authors:  Christopher K Murphy; Steve Mullin; Marcia S Osburne; John van Duzer; Jim Siedlecki; Xiang Yu; Kathy Kerstein; Michael Cynamon; David M Rothstein
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.